Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsIn 2026, Zylox-Tonbridge Medical Technology Co Ltd Class H has already paid €0.028 in dividends. The last payout was in June.
Financials
In the last quarter, Zylox-Tonbridge Medical Technology Co Ltd Class H had revenue of €81.51M and net profit of €23.43M
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 81.51M | - |
| Gross profit | 59.83M | - |
| Net profit | 23.43M | - |
| EBITDA | 25.65M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €639.15M |
Number of shares | 322.06M |
52-week high/low | €3.21 - €1.95 |
Dividend yield | 1.30% |
Dividends TTM | €0.028 |
Beta | 0.31 |
P/E ratio | 15.27 |
PEG ratio | 0.15 |
P/B ratio | 1.55 |
P/S ratio | 3.87 |
Company profile
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.
| Name | Zylox-Tonbridge Medical Technology Co Ltd Class H |
| CEO | Zhong Zhao |
| Headquarters | Hangzhou,
zh China |
| Website | |
| IPO | 07/05/2021 |
| Employees | 1,214 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Hkse | 2190.HK |
Frankfurt | 818.F |
Düsseldorf | 818.DU |
München | 818.MU |